For most pre-seed biotech founders, the choice between a SAFE and a convertible note depends on four factors: your development stage, your investor base, your jurisdiction, and your timeline to a priced round. This is not a generic startup finance question. The structural differences between these instruments carry consequences that compound over the multi-year preclinical timelines that define life sciences, and picking the wrong one can create a repayment cliff or dilution event at exactly the moment you need capital freedom most.
Why the SAFE vs Convertible Note Decision Hits Differently in Biotech
Biotech development timelines create structural mismatches with instruments designed for eighteen-month software cycles. A pre-seed software company might close a SAFE, ship a product, and reach a Series A within two years. A pre-seed biotech company raising capital before IND-enabling studies might not reach a priced round for four to six years, if the science holds. That gap changes everything about how you evaluate these instruments.
Capital intensity compounds the problem. Biotech founders aren’t just waiting longer for a priced round. They’re burning through capital on CRO contracts, IP filing, and regulatory preparation the entire time. The instrument you choose at pre-seed will sit on your cap table through those years, accruing interest or not, converting or not, and creating legal obligations that interact with every subsequent funding decision.
The stakes are direct: a convertible note with a 24-month maturity date signed before IND-enabling studies begin can reach its repayment deadline before you have proof-of-concept data. That’s not a hypothetical risk. It’s a structural feature of the instrument that most generic startup finance guides don’t address, because they’re written for founders whose “long timeline” is 18 months.
Structural Mechanics: What Each Instrument Actually Is
A convertible note is debt. It carries an interest rate, a maturity date, and a legal obligation to repay principal plus accrued interest if conversion to equity does not occur. The note converts into equity at a priced round, typically at a discount to the round price or at a valuation cap, whichever produces more shares for the investor. If no qualifying financing event happens before the maturity date, the investor can demand repayment.
A SAFE (Simple Agreement for Future Equity) is not debt. Y Combinator introduced the SAFE in 2013 as a simpler alternative to convertible notes for early-stage raises. It is a contractual right to receive equity at a future priced round or liquidity event, with no interest accrual and no maturity date. The post-money SAFE, which became the Y Combinator standard in 2018, calculates the investor’s ownership percentage at the time of signing rather than at conversion, giving founders and investors clearer dilution visibility upfront. The pre-money SAFE, the earlier version, calculated ownership at conversion, which created uncertainty about final dilution.
| Term | SAFE | Convertible Note |
|---|---|---|
| Valuation cap | Maximum valuation at which SAFE converts to equity | Maximum valuation at which note converts to equity |
| Discount rate | Percentage reduction on Series A price at conversion | Percentage reduction on Series A price at conversion |
| MFN clause | Investor gets best terms offered to later SAFE investors | Less common; can be negotiated |
| Pro-rata rights | Right to participate in future rounds | Right to participate in future rounds |
| Interest | None | Typically 6–8% per annum |
| Maturity date | None | Typically 12–24 months |
The most favoured nation (MFN) clause deserves attention for early biotech rounds where valuation is genuinely uncertain. An uncapped SAFE with an MFN clause allows an early investor to adopt the terms of any subsequent SAFE issued at better terms, which protects investors who come in before proof-of-concept data without requiring a fixed valuation cap. For a preclinical company where a Phase I readout could shift perceived value by an order of magnitude, this flexibility can make early conversations with angels easier.
The Dilution Maths: How Biotech Timelines Change the Calculation
The key difference between a SAFE and a convertible note, in pure dilution terms, is interest. A £500K convertible note at 8% annual interest, if it sits unconverted for three years, accrues roughly £120K in interest. That interest converts into equity at the same terms as the principal, meaning investors receive more shares than they paid for. On a typical biotech pre-seed round, this interest accrual adds approximately 2% of equity dilution and a hard repayment deadline that constrains your next-round timing.
Consider the cap mechanics directly. If you raise £500K on a convertible note with a £5M valuation cap and 8% interest over three years, the note principal plus interest converts at the cap price. The investor ends up with a larger ownership percentage than if they had invested the same £500K on a SAFE at the same cap. Founders who use a SAFE instead preserve approximately 2% of equity per year by skipping interest and remove the repayment deadline entirely.
The discount rate compounds this effect. A 20% discount on a £2M Series A means the note converts at £1.6M equivalent pricing. If your Series A values the company at £10M, an investor who put in £500K on a capped SAFE at £5M gets 10% of the company. An investor on an uncapped SAFE with only a 20% discount converts at 50% of the round price, which in some scenarios could mean converting at a price that gives them 25% of the company rather than 5%. Valuation cap and discount mechanics interact, and the interaction matters more when your Series A is three years away rather than eighteen months.
Investor Expectations by Type: Who Prefers What and Why
Angel investors and family offices, which are common early capital sources in biotech, frequently prefer convertible notes. The debt structure feels more familiar to non-institutional investors who have experience with loan agreements but less with equity instruments. The interest rate provides a return signal even before conversion, and the maturity date creates a defined timeline for resolution. If you’re raising from a high-net-worth individual with a background in property or traditional finance rather than venture capital, a convertible note may close faster than a SAFE.
Institutional pre-seed funds and accelerators operating in the Y Combinator model strongly prefer SAFEs. The Y Combinator post-money SAFE template is a standardised document that experienced investors can review and sign quickly, reducing legal costs and closing time. According to Carta’s platform data, SAFEs now represent 90% of pre-seed deals in the US market, reflecting this institutional preference. If your lead investor is an accelerator or a dedicated pre-seed fund, expect them to push for a SAFE.
European and UK biotech investors occupy a more varied position. Many UK angels are comfortable with either instrument, but the convertible loan note (CLN) remains structurally more common in UK early-stage deals than the SAFE. This reflects both legal familiarity and tax incentive interactions discussed below. German and French institutional investors tend to prefer priced rounds even at early stages, making both SAFEs and convertible notes less common in those markets than in the UK or US.
European and UK Context: Jurisdiction, Tax, and Grant Compatibility
SAFEs originated under US legal conventions and are not natively recognised in all European legal frameworks. In England and Wales, a SAFE can be drafted as a legally enforceable contract, but it requires careful drafting to ensure it doesn’t inadvertently constitute a regulated financial instrument. UK founders should confirm enforceability with a life sciences solicitor before presenting a SAFE to investors, as the consequences of a poorly drafted instrument extend to every future financing event.
EIS and SEIS Compatibility
EIS (Enterprise Investment Scheme) and SEIS (Seed Enterprise Investment Scheme) tax relief are significant incentives for UK angel investors. Under EIS, investors receive 30% income tax relief on investments up to £1M per year. Under SEIS, the relief is 50% on investments up to £200K. These schemes interact differently with SAFEs and convertible notes, and the wrong structure can disqualify investors from relief entirely.
A SAFE does not constitute an equity share at the point of investment, which means EIS/SEIS relief is typically not available at the time of the SAFE signing. Relief may become available at conversion, but HMRC’s position on this has been subject to interpretation. A properly structured convertible loan note can qualify for EIS/SEIS relief at the point of investment under certain conditions. If your investor base includes UK angels who need EIS/SEIS relief to make the investment economics work, a convertible note structured to meet HMRC requirements may be the only viable instrument.
Grant Stacking with Innovate UK and EIC
Innovate UK grants and EIC Accelerator co-investment are non-dilutive and can be stacked alongside either instrument. The timing of grant drawdown relative to note conversion requires planning. EIC Accelerator co-investment, which provides equity investment alongside the grant component, will trigger a priced round and therefore a conversion event for any outstanding SAFEs or convertible notes. If your convertible note has a maturity date approaching when EIC co-investment closes, the conversion mechanics need to be agreed in advance to avoid a forced repayment scenario. Founders pursuing EIC funding should flag outstanding convertible instruments to their legal team early in the application process.
What Happens When Conversion Does Not Occur
A SAFE that never converts leaves investors holding a contractual right with no equity and no repayment right. In biotech, where companies sometimes pivot, wind down, or get acquired before a priced round, this scenario is more common than in software. On dissolution, SAFE investors typically have rights ahead of common shareholders but behind debt holders. The Y Combinator post-money SAFE template includes dissolution rights that give SAFE holders a return of their investment amount before common shareholders receive anything, but this protection is only as valuable as the company’s remaining assets.
A convertible note that reaches maturity without a qualifying financing event gives investors the right to demand repayment of principal plus accrued interest. For a biotech company that has spent its capital on preclinical studies, this can force insolvency. The maturity date risk is real, and it’s more dangerous in biotech than in software precisely because IND-enabling timelines, CRO delays, and regulatory feedback cycles can push a priced round beyond any maturity date set at pre-seed. Founders should negotiate maturity dates of at least 24 to 36 months and include automatic extension provisions tied to development milestones.
Key Terms to Negotiate Regardless of Instrument
Your valuation cap should reflect your expected Series A valuation range, not your current perceived value. A cap that looks reasonable before a successful Phase I readout can produce severe dilution after one. If your preclinical data is strong and your Series A target is £15M to £20M, a cap set at £5M means early investors convert at a significant discount to your eventual value, which is appropriate for the risk they took but should be modelled explicitly before you agree to it.
A discount rate of 15 to 20% is standard. Anything above 20% is aggressive and should be challenged, as it compounds with the cap to increase investor returns at your expense. If an investor is asking for both a low cap and a high discount rate, they’re seeking double protection that isn’t market standard for pre-seed biotech.
Pro-rata rights give investors the right to participate in future rounds to maintain their ownership percentage. Founders should define these rights explicitly in the instrument, as ambiguity creates friction at Series A when new investors are negotiating allocation. Consider whether pro-rata rights apply to all future rounds or only the next priced round, and whether they are subject to a minimum ownership threshold.
A Step-by-Step Decision Framework for Biotech Founders
The following framework applies to pre-seed and seed-stage biotech companies evaluating which instrument to use. Work through each step in order.
- Identify your investor type. If your lead investor is an institutional pre-seed fund or accelerator, they likely expect a SAFE. If they are angels or family offices, a convertible note may close more easily.
- Confirm your jurisdiction. UK founders must verify SAFE enforceability and EIS/SEIS compatibility before presenting the instrument. If EIS/SEIS relief is material to your investors, a convertible loan note structured to HMRC requirements is likely the right choice.
- Map your timeline to a priced round. If your Series A is more than 18 months away and milestone-dependent, the absence of a maturity date on a SAFE is a material advantage. If you expect a priced round within 12 to 18 months, a convertible note’s maturity risk is manageable.
- Assess your capital structure complexity. If you are raising in tranches tied to specific milestones, a convertible note’s structured drawdown mechanics may be more appropriate than a SAFE.
- Check grant interactions. If you are pursuing Innovate UK, EIC Accelerator, or equivalent non-dilutive funding, confirm that your chosen instrument’s conversion triggers align with the expected grant timeline.
- Model the dilution scenarios. Run the numbers at your expected Series A valuation using both instruments. The difference in equity percentage at conversion, accounting for interest on the note, should inform your final decision.
- Engage a life sciences solicitor before signing. This article provides informational analysis only and does not constitute legal or financial advice. The instrument you choose has legal consequences that extend to every future financing event, and specialist counsel is not optional.
Use a SAFE if your lead investor is comfortable with the instrument, your Series A is more than 18 months away, you want to avoid interest accrual, and you are raising from accelerator-affiliated or institutional pre-seed investors. Use a convertible note if your investors are angels or family offices who require debt protections, you are in a jurisdiction where SAFEs have uncertain legal standing, or your raise is structured in tranches tied to specific milestones. In either case, negotiate a valuation cap that reflects your post-milestone value, set a maturity date of at least 24 to 36 months, and confirm EIS/SEIS compatibility before closing.
Frequently Asked Questions
Which is better for a biotech startup, a SAFE or a convertible note?
Neither instrument is universally better. The right choice depends on your investor type, jurisdiction, and timeline to a priced round. SAFEs are simpler and avoid interest accrual, which matters when your Series A is three or more years away. Convertible notes offer debt protections that some angel investors require and may be necessary for UK EIS/SEIS compatibility.
Does a convertible note’s maturity date create risk for biotech founders?
Yes, and more so than for software founders. Biotech development timelines can extend well beyond the 12 to 24 month maturity dates common in convertible notes. If a qualifying financing event doesn’t occur before maturity, investors can demand repayment. Founders should negotiate maturity dates of at least 24 to 36 months with automatic extension provisions.
Do European biotech investors prefer SAFEs or convertible notes?
European preferences vary by market. UK investors are familiar with both instruments, though convertible loan notes remain more common. German and French institutional investors often prefer priced rounds. Founders should confirm instrument preferences with their specific investor base before drafting term sheets.
Can I stack an Innovate UK grant with a SAFE or convertible note?
Yes. Non-dilutive grants from Innovate UK or EIC Accelerator can be stacked alongside either instrument. The key consideration is timing: EIC Accelerator co-investment triggers a priced round and therefore a conversion event, so outstanding convertible instruments need to be accounted for in the closing mechanics.
What happens to a SAFE if my biotech company never reaches a priced round?
A SAFE that never converts leaves investors with no equity and no repayment right. On dissolution, SAFE holders typically have rights ahead of common shareholders but behind debt holders. In biotech, where companies sometimes wind down before a Series A, founders should ensure SAFE terms include clear dissolution rights to manage investor expectations.
This article provides informational analysis only and does not constitute legal or financial advice. Instrument selection has legal consequences that extend to every future financing event. Engage a specialist life sciences solicitor before executing either a SAFE or a convertible note.
- Codon Optimisation Strategies That Actually Improve Recombinant Protein Yield - August 31, 2026
- Convertible Note vs SAFE for Biotech: A Founder’s Decision Framework - August 24, 2026
- EMA Centralised vs National Authorisation: Which Route Fits Your Drug? - August 17, 2026